The British Journal of Haematology has published the results of two phase II studies which showed strong single agent and very high combination response rates in front-line multiple myeloma for Millennium Pharmaceuticals' Velcade. Release [1]
Links:
[1] http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-08-2005/0003824398&EDATE=